TransMedics: Q4 net income of $105.4M included $83.8M tax benefit; adjusted $17.5M
TransMedics added detail to its fourth-quarter 2025 results, showing that a $103.3 million release of a U.S. tax valuation allowance produced a $83.8 million net income tax benefit. At a 19.1% annual effective tax rate, fourth-quarter net income would be $17.5 million, or $0.47 per diluted share, versus the reported $105.4 million, or $2.62 per share. The company expects future quarterly tax provisions to be more in line with U.S. statutory rates.
Key points
- Released $103.3 million U.S. tax valuation allowance in Q4 2025, producing an $83.8 million net income tax benefit
- Reported Q4 2025 net income of $105.4 million ($2.62 per diluted share); adjusted net income of $17.5 million ($0.47 per share)
- 2025 annual effective tax rate was (77.0)%; excluding the release, it would have been 19.1%
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.